This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thomas, M. B. Articles by Abbruzzese, J. L. Search for Related Content PubMed PubMed Citation Articles by Thomas, M. B. Articles by Abbruzzese, J. L.

Opportunities for Targeted Therapies in Hepatocellular Carcinoma

From the Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Address reprint requests to Melanie B. Thomas, MD, Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 426, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: methomas{at}mdanderson.org

Hepatocellular cancer (HCC) is the fifth most common solid tumor worldwide, accounting for 500,000 new cases annually. Although less common in the United States, HCC is expected to increase in incidence over the next two decades largely because of the prevalence of hepatitis C virus infection. A majority of patients present with advanced disease and are not candidates for liver transplantation, surgical resection, or regional therapy. In 60% to 80% of patients with HCC, treatment is complicated by underlying liver cirrhosis and hepatic dysfunction. Systemic treatments are minimally effective, can have significant toxicity, and have not been shown to improve patient survival. New approaches targeting molecular abnormalities specific to HCC are needed to improve patient outcome. This review summarizes the state of knowledge of those key aspects of the molecular pathogenesis of HCC that may represent rational therapeutic targets in this disease. Relevant preclinical and clinical information on novel compounds directed toward abnormalities in HCC is reviewed.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				A. B. Siegel, E. I. Cohen, A. Ocean, D. Lehrer, A. Goldenberg, J. J. Knox, H. Chen, S. Clark-Garvey, A. Weinberg, J. Mandeli, et al. Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma J. Clin. Oncol., June 20, 2008; 26(18): 2992 - 2998. [Abstract] [Full Text] [PDF]

				S. Krishnan, L. A. Dawson, J. Seong, Y. Akine, S. Beddar, T. M. Briere, C. H. Crane, and F. Mornex Radiotherapy for Hepatocellular Carcinoma: An Overview Ann. Surg. Oncol., April 1, 2008; 15(4): 1015 - 1024. [Full Text] [PDF]

				B. C. Fuchs, T. Fujii, J. D. Dorfman, J. M. Goodwin, A. X. Zhu, M. Lanuti, and K. K. Tanabe Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells Cancer Res., April 1, 2008; 68(7): 2391 - 2399. [Abstract] [Full Text] [PDF]

				H. Huynh, P. K.H. Chow, and K.-C. Soo AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma Mol. Cancer Ther., September 1, 2007; 6(9): 2468 - 2476. [Abstract] [Full Text] [PDF]

				H. Hung Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts Mol. Cancer Ther., August 1, 2007; 6(8): 2149 - 2157. [Abstract] [Full Text] [PDF]

				A. X. Zhu Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? Oncologist, July 1, 2006; 11(7): 790 - 800. [Abstract] [Full Text] [PDF]

				J. Castillo, E. Erroba, M. J. Perugorria, M. Santamaria, D. C. Lee, J. Prieto, M. A. Avila, and C. Berasain Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res., June 15, 2006; 66(12): 6129 - 6138. [Abstract] [Full Text] [PDF]